Atazanavir and cobicistat: new combination HIV drug

on the 28 August 2015

Evotaz, a combination drug consisting of the protease inhibitor atazanavir (Reyataz) and the pharmacoenhancer cobicistat (Tybost), has been launched by Bristol-Myers Squibb.

Further information
View Evotaz drug record 
Summary of Product Characteristics
Manufacturer: Bristol-Myers Squibb

The 300mg/150mg tablets are licensed in combination with other antiretrovirals for the treatment of HIV-1 infected patients without known mutations associated with atazanavir resistance.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...